Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.
AUTOR(ES)
Kordower, J H
RESUMO
Intrastriatal injections of quinolinic acid induce a pattern of neuronal degeneration similar to that seen in Huntington disease. In the present study, nerve growth factor (NGF) crossed the blood-brain barrier in a dose-dependent fashion following intravenous infusion when conjugated to an antibody directed against the transferrin receptor (OX-26). Intravenous injections of the OX-26-NGF conjugate selectively prevented the loss of striatal choline acetyltransferase-immunoreactive neurons which normally occurs following quinolinic acid administration relative to control rats receiving vehicle or a nonconjugated mixture of OX-26 and NGF. These data demonstrate that a neurotrophic factor-antibody conjugate can prevent the degeneration of central NGF-responsive neurons following systemic administration.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44750Documentos Relacionados
- Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
- Differential loss of striatal projection neurons in Huntington disease.
- Nerve growth factor promotes cholinergic development in brain striatal cultures.
- Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease.
- Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease.
